NCT05223894 - Treating Heart Failure With hiPSC-CMs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Heart Failure

Interventions

BIOLOGICAL

hiPSC-CM therapy

Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.

OTHER

Control

Coronary artery bypass grafting surgery only.

Trial Locations (1)

Unknown

RECRUITING

Shanghai east Hospital, Shanghai